New Key Statistics Module, Z-Score and F-Score
NAS:ACRS Key Ratios
| Market Cap $ M | 282.87 |
| Enterprise Value $ M | 172.04 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 2.18 |
| Price/Sales | 10.34 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 27.00 |
| EPS (TTM) $ | -0.52 |
| Beneish M-Score | -3.9 |
| 10-y EBITDA Growth Rate % | -3.10 |
| 5-y EBITDA Growth Rate % | 9.50 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -2.77 |
| EV-to-EBITDA | -2.81 |
| PEG | -- |
| Shares Outstanding M | 71.43 |
| Net Margin (%) | -136.65 |
| Operating Margin % | -229.59 |
| Pre-tax Margin (%) | -138.00 |
| Quick Ratio | 7.03 |
| Current Ratio | 7.03 |
| ROA % (ttm) | -19.82 |
| ROE % (ttm) | -25.72 |
| ROIC % (ttm) | -94.69 |
| Dividend Yield % | -- |
| Altman Z-Score | -2.63 |
ACRS Number of Guru Trades
ACRS Volume of Guru Trades
Gurus Latest Trades with NAS:ACRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ACRS is held by these investors
Total 1
Aclaris Therapeutics Inc Insider Transactions
No Available Data
News about NAS:ACRS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers